Publications by authors named "Pnina Fishman"

Claim this Profile
A
A long‑term complete response to namodenoson in liver cancer with Child‑Pugh B cirrhosis: A case report.
Ioana Adriana Ciurescu, Riccardo Lencioni, Salomon M Stemmer, Motti Farbstein, Zivit Harpaz, Pnina Fishman

Exp Ther Med· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Namodenoson at the Crossroad of Metabolic Dysfunction-Associated Steatohepatitis and Hepatocellular Carcinoma.
Ohad Etzion, Avital Bareket-Samish, David Yardeni, Pnina Fishman

Biomedicines· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Namodenoson Inhibits the Growth of Pancreatic Carcinoma via Deregulation of the Wnt/β-catenin, NF-κB, and RAS Signaling Pathways.
Inbal Itzhak, Avital Bareket-Samish, Pnina Fishman

Biomolecules· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Targeting the A3 adenosine receptor to treat hepatocellular carcinoma: anti-cancer and hepatoprotective effects.
Pnina Fishman, Salomon M Stemmer, Avital Bareket-Samish, Michael H Silverman, William D Kerns

Purinergic Signal· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A3 adenosine receptor allosteric modulator CF602 reverses erectile dysfunction in a diabetic rat model.
Inbal Itzhak, Shira Cohen, Sari Fishman, Pnina Fishman

Andrologia· October 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Drugs Targeting the A3 Adenosine Receptor: Human Clinical Study Data.
Pnina Fishman

Molecules· June 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Editorial: targeting aberrant hepatic inflammation for treatment of non-alcoholic steatohepatitis-authors' reply.
Rifaat Safadi, Marius Braun, Adi Francis, Yael Milgrom, Muhammad Massarwa, Pnina Fishman

Aliment Pharmacol Ther· February 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Randomised clinical trial: A phase 2 double-blind study of namodenoson in non-alcoholic fatty liver disease and steatohepatitis.
Rifaat Safadi, Marius Braun, Adi Francis, Yael Milgrom, Muhammad Massarwa, Pnina Fishman

Aliment Pharmacol Ther· December 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Namodenoson in Advanced Hepatocellular Carcinoma and Child-Pugh B Cirrhosis: Randomized Placebo-Controlled Clinical Trial.
Salomon M Stemmer, Nebojsa S Manojlovic, Mihai Vasile Marinca, Petar Petrov, Nelly Cherciu, Pnina Fishman

Cancers (Basel)· January 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The A3 adenosine receptor agonist, namodenoson, ameliorates non‑alcoholic steatohepatitis in mice.
Pnina Fishman, Shira Cohen, Inbal Itzhak, Johnny Amer, Ahmad Salhab

Int J Mol Med· December 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Targeting the A adenosine receptor to treat cytokine release syndrome in cancer immunotherapy.
Shira Cohen, Pnina Fishman

Drug Des Devel Ther· August 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Inhibition of IL-17 and IL-23 in Human Keratinocytes by the A Adenosine Receptor Agonist Piclidenoson.
Shira Cohen, Faina Barer, Inbal Itzhak, Michael H Silverman, Pnina Fishman

J Immunol Res· October 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A3 adenosine receptor agonist, CF102, protects against hepatic ischemia/reperfusion injury following partial hepatectomy.
Gil Ohana, Shira Cohen, Lea Rath-Wolfson, Pnina Fishman

Mol Med Rep· November 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The A3 adenosine receptor (A3AR): therapeutic target and predictive biological marker in rheumatoid arthritis.
Pnina Fishman, Shira Cohen

Clin Rheumatol· September 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Treatment of Plaque-Type Psoriasis With Oral CF101: Data from a Phase II/III Multicenter, Randomized, Controlled Trial.
Michael David, Dimitar Konstantinov Gospodinov, Nicola Gheorghe, Grisha Stefanov Mateev, Mariyana Venelinova Rusinova, Pnina Fishman

J Drugs Dermatol· August 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A₃ adenosine receptor allosteric modulator induces an anti-inflammatory effect: in vivo studies and molecular mechanism of action.
Shira Cohen, Faina Barer, Sara Bar-Yehuda, Adriaan P IJzerman, Kenneth A Jacobson, Pnina Fishman

Mediators Inflamm· July 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
CF102 for the treatment of hepatocellular carcinoma: a phase I/II, open-label, dose-escalation study.
Salomon M Stemmer, Ofer Benjaminov, Gal Medalia, Noab B Ciuraru, Michael H Silverman, Sari Fishman, Pnina Fishman

Oncologist· July 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Targeting the A3 adenosine receptor for glaucoma treatment (review).
Pnina Fishman, Shira Cohen, Sara Bar-Yehuda

Mol Med Rep· June 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacological and therapeutic effects of A3 adenosine receptor agonists.
Pnina Fishman, Sara Bar-Yehuda, Bruce T Liang, Kenneth A Jacobson

Drug Discov Today· April 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Putative role of the adenosine A(3) receptor in the antiproliferative action of N (6)-(2-isopentenyl)adenosine.
Clara C Blad, Jacobien K von Frijtag Drabbe Künzel, Henk de Vries, Thea Mulder-Krieger, Sara Bar-Yehuda, Pnina Fishman

Purinergic Signal· December 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Inhibition of experimental auto-immune uveitis by the A3 adenosine receptor agonist CF101.
Sara Bar-Yehuda, Dror Luger, Avivit Ochaion, Shira Cohen, Renana Patokaa, Pnina Fishman

Int J Mol Med· November 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Treatment of dry eye syndrome with orally administered CF101: data from a phase 2 clinical trial.
Isaac Avni, Hanna J Garzozi, Irina S Barequet, Fanni Segev, David Varssano, Sari Fishman, Pnina Fishman

Ophthalmology· July 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical evidence for utilization of the A3 adenosine receptor as a target to treat rheumatoid arthritis: data from a phase II clinical trial.
Michael H Silverman, Vibeke Strand, Doron Markovits, Menachem Nahir, Tatiana Reitblat, Sari Fishman-Furman, Pnina Fishman

J Rheumatol· January 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The anti-inflammatory effect of A3 adenosine receptor agonists: a novel targeted therapy for rheumatoid arthritis.
Sara Bar-Yehuda, Michael H Silverman, William D Kerns, Avivit Ochaion, Shira Cohen, Pnina Fishman

Expert Opin Investig Drugs· October 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Overexpression of A3 adenosine receptor in peripheral blood mononuclear cells in rheumatoid arthritis: involvement of nuclear factor-kappaB in mediating receptor level.
Lea Madi, Shira Cohen, Avivit Ochayin, Sara Bar-Yehuda, Faina Barer, Pnina Fishman

J Rheumatol· January 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis